María Teresa Blasco

María Teresa Blasco

Auto-generated profile, based on publicly available information

María Teresa Blasco

Cancer Science Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
MDMagdolna Djurec
Magdolna Djurec
OGOsvaldo Graña
Osvaldo Graña
ALAlbert Lee
Albert Lee
KTKevin Troulé
Kevin Troulé
EEElisa Espinet
Elisa Espinet
MBMariano Barbacid
Mariano Barbacid
Significance: Pancreatic ductal adenocarcinoma is one of the most malignant human tumors for which there are no efficacious therapeutic strategies. This tumor type is characterized by an abundant desmoplastic stroma that promotes tumor progression. Yet recent studies have shown that physical or genetic elimination of the stroma leads to more aggressive tumor development. Here, we decided to reprogram the stromal tissue by identifying and subsequently targeting genes responsible for their protumorigenic properties. Comparative transcriptome analysis revealed several genes overexpressed in cancer-associated fibroblasts compared with those present in normal pancreata. We provide genetic evidence that one of these genes, Saa3 , plays a key role on the protumorigenic properties of the stroma, opening the door to the design of future therapeutic strategies.

1 April 2019 in Cancer Cell
Verified
Journal Article
Closed access
MBMaría Teresa Blasco
María Teresa Blasco
CNCarolina Navas
Carolina Navas
GMGuillermo Martín-Serrano
Guillermo Martín-Serrano
OGOsvaldo Graña-Castro
Osvaldo Graña-Castro
CLCarmen G. Lechuga
Carmen G. Lechuga
MBMariano Barbacid
Mariano Barbacid

2 August 2017 in Nature
Verified
Journal Article
Closed access
PDF file
PNPatricia Nieto
Patricia Nieto
CAChiara Ambrogio
Chiara Ambrogio
LELaura Esteban-Burgos
Laura Esteban-Burgos
Gonzalo Gomez-LopezGonzalo Gomez-Lopez
Gonzalo Gomez-Lopez
MBMaría Teresa Blasco
María Teresa Blasco
David SantamariaDavid Santamaria
David Santamaria

1 November 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
JUJelena Urosevic
Jelena Urosevic
MBMaría Teresa Blasco
María Teresa Blasco
ALAlicia Llorente
Alicia Llorente
ABAnna Bellmunt
Anna Bellmunt
ABAntoni Berenguer-Llergo
Antoni Berenguer-Llergo
RGRoger R. Gomis
Roger R. Gomis
Carcinoma development in colorectal cancer is driven by genetic alterations in numerous signaling pathways. Alterations in the RAS-ERK1/2 pathway are associated with the shortest overall survival for patients after diagnosis of colorectal cancer metastatic disease, yet how RAS–ERK signaling regulates colorectal cancer metastasis remains unknown. In this study, we used an unbiased screening approach based on selection of highly liver metastatic colorectal cancer cells in vivo to determine genes associated with metastasis. From this, an ERK1/2-controlled metastatic gene set (EMGS) was defined. EMGS was associated with increased recurrence and reduced survival in patients with colorectal cancer tumors. Higher levels of EMGS expression were detected in the colorectal cancer subsets consensus molecular subtype (CMS)1 and CMS4. ANGPT2 and CXCR4, two genes within the EMGS, were subjected to gain-of-function and loss-of-function studies in several colorectal cancer cell lines and then tested in clinical samples. The RAS–ERK1/2 axis controlled expression of the cytokine ANGPT2 and the cytokine receptor CXCR4 in colorectal cancer cells, which facilitated development of liver but not lung metastases, suggesting that ANGPT2 and CXCR4 are important for metastatic outgrowth in the liver. CXCR4 controlled the expression of cytokines IL10 and CXCL1, providing evidence for a causal role of IL10 in supporting liver colonization. In summary, these studies demonstrate that amplification of ERK1/2 signaling in KRAS-mutated colorectal cancer cells affects the cytokine milieu of the tumors, possibly affecting tumor–stroma interactions and favoring liver metastasis formation. Significance: These findings identify amplified ERK1/2 signaling in KRAS-mutated colorectal cancer cells as a driver of tumor–stroma interactions that favor formation of metastases in the liver.

31 January 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
MDMatthias Drosten
Matthias Drosten
LSLucía Simón-Carrasco
Lucía Simón-Carrasco
IHIsabel Hernández-Porras
Isabel Hernández-Porras
CLCarmen G. Lechuga
Carmen G. Lechuga
MBMaría T. Blasco
María T. Blasco
MBMariano Barbacid
Mariano Barbacid
Genetic studies in mice have provided evidence that H-Ras and K-Ras proteins are bioequivalent. However, human tumors display marked differences in the association of RAS oncogenes with tumor type. Thus, to further assess the bioequivalence of oncogenic H-Ras and K-Ras, we replaced the coding region of the murine K-Ras locus with H-RasG12V oncogene sequences. Germline expression of H-RasG12V or K-RasG12V from the K-Ras locus resulted in embryonic lethality. However, expression of these genes in adult mice led to different tumor phenotypes. Whereas H-RasG12V elicited papillomas and hematopoietic tumors, K-RasG12V induced lung tumors and gastric lesions. Pulmonary expression of H-RasG12V created a senescence-like state caused by excessive MAPK signaling. Likewise, H-RasG12V but not K-RasG12V induced senescence in mouse embryonic fibroblasts. Label-free quantitative analysis revealed that minor differences in H-RasG12V expression levels led to drastically different biological outputs, suggesting that subtle differences in MAPK signaling confer nonequivalent functions that influence tumor spectra induced by RAS oncoproteins. Cancer Res; 77(3); 707–18. ©2016 AACR.

9 November 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ALAlicia Llorente
Alicia Llorente
MBMaría Teresa Blasco
María Teresa Blasco
IEIrene Espuny
Irene Espuny
MGMarc Guiu
Marc Guiu
CBCecilia Ballaré
Cecilia Ballaré
RGRoger R. Gomis
Roger R. Gomis
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility and functional assays from human and syngeneic mouse BCa models to show that MAF directly interacts with oestrogen receptor alpha (ERα), thereby promoting a unique chromatin landscape that favours metastatic spread. We identify metastasis-promoting genes that are de novo licensed following oestrogen exposure in a MAF-dependent manner. The histone demethylase KDM1A is key to the epigenomic remodelling that facilitates the expression of the pro-metastatic MAF/oestrogen-driven gene expression program, and loss of KDM1A activity prevents this metastasis. We have thus determined that the molecular basis underlying MAF/oestrogen-mediated metastasis requires genetic, epigenetic and hormone signals from the systemic environment, which influence the ability of BCa cells to metastasize.